Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.allogene.com
Allogene Therapeutics News Releases
Get the latest updates from Allogene Therapeutics News Releases directly as they happen.
Follow now 95 followers
Latest posts
Last updated about 5 hours ago
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
about 6 hours ago
Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms...
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
about 1 month ago
SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
about 1 month ago
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line...
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
about 1 month ago
SOUTH SAN FRANCISCO, Calif. , Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
about 2 months ago
Conference Call and Webcast Scheduled for November 6, 2025 at 2:00 p.m...
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
4 months ago
SOUTH SAN FRANCISCO, Calif. , Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
4 months ago
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line...
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
4 months ago
Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m...
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
5 months ago
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety...
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
7 months ago
Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1...
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
7 months ago
SOUTH SAN FRANCISCO, Calif. , May 23, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
7 months ago
SOUTH SAN FRANCISCO, Calif. , May 22, 2025 (GLOBE NEWSWIRE) -- Allogene...